ClinicalTrials.gg
RecruitingNCT07413666Updated Feb 25, 2026

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

A Phase 1 interventional study of ORX489 Tablets and Placebo Tablets in Healthy Adult Male and Female Volunteers, sponsored by Centessa Pharmaceuticals (UK) Limited. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Centessa Pharmaceuticals (UK) Limited (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.

02

Conditions studied

  • Healthy Adult Male and Female Volunteers

Keywords

  • Healthy Volunteers orexin-2 receptor agonist
03

In context

Lead sponsor

Centessa Pharmaceuticals (UK) Limited is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

First submitted before Centessa Pharmaceuticals (UK) Limited became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females as determined by assessments at the Screening Visit.
  • For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening

Exclusion criteria

Exclusion Criteria:

  • Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, , endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.
  • History of seizure disorder, any other condition that increases the risk of seizure
  • Has a sleep disorder, including insomnia or sleep apnea
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    Part A

    SAD Study in Healthy Adults: ORX489 and Placebo

    Drug: ORX489 Tablets · Other: Placebo Tablets

  • Experimental
    Part B

    Food-effect Evaluation in Healthy Adults: ORX489

    Drug: ORX489 Tablets

  • Experimental
    Part C

    MAD Study in Healthy Adults: ORX489 and Placebo

    Drug: ORX489 Tablets · Other: Placebo Tablets

  • Experimental
    Part D

    SAD Study in Acutely Sleep-Deprived Healthy Adults: ORX489 and Placebo

    Drug: ORX489 Tablets · Other: Placebo Tablets

Interventions

  • DrugORX489 Tablets

    ORX489 Tablets

  • OtherPlacebo Tablets

    Placebo Tablets

06

What researchers measure

Primary outcomes

  1. Part A

    Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral single ascending doses of ORX489 in healthy adult participants.

    Time frame: From enrollment to the Follow-Up Visit 7 days post-discharge

  2. Part B

    Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral single ascending doses of ORX489 in the fasted and fed states

    Time frame: From enrollment to the Follow-Up Visit 7 days post-discharge]

  3. Part C

    Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral multiple ascending doses of ORX489 in healthy adult participants

    Time frame: From enrollment to the Follow-Up Visit 7 days post-discharge]

  4. Part D:

    Incidence and severity of Treatment-Emergent Adverse Events \[Safety and Tolerability\] as assessed by AEs and SAEs of oral single oral doses of ORX489 in sleep-deprived healthy adult participants

    Time frame: From enrollment to the Follow-Up Visit 7 days post-discharge

Secondary outcomes

  1. Cmax

    Maximum Observed Plasma Concentration for ORX489 in participants receiving ORX489

    Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours

  2. Tmax

    Time of Maximum Concentration for ORX489 in participants receiving ORX489

    Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours

  3. AUClast

    Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for ORX489 in participants receiving ORX489

    Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours

  4. T 1/2 (terminal elimination half-life)

    The time required for the terminal phase blood concentration of ORX489 to decrease by half in participants receiving ORX489

    Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours

  5. Cmax

    Maximum Observed Plasma Concentration for ORX489 in participants receiving ORX489 in the fasted and fed state.

    Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours

  6. Tmax

    Time of Maximum Concentration for ORX489 in participants receiving ORX489 in the fast and fed state

    Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours

  7. AUClast

    Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for ORX489 in participants receiving ORX489 in the fast and fed state

    Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours

  8. T 1/2 (terminal elimination half-life)

    The time required for the terminal phase blood concentration of ORX489 to decrease by half in participants receiving ORX489 in the fast and fed state

    Time frame: Pre-dose and multiple post-dose timepoints, up to 48 hours

  9. Mean sleep latency in the Maintenance of Wakefulness Test (MWT)

    Mean sleep latency in the Maintenance of Wakefulness Test (MWT) for ORX489 versus placebo: MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake

    Time frame: Part D: Day 1-2

  10. Karolinska Sleepiness Scale score

    Karolinska Sleepiness Scale score for ORX489 versus placebo: 9-point scale, ranging from "extremely alert" (1) to "very sleepy, great effort keeping awake, fighting sleep

    Time frame: Part D: Day 1-2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Jun 2027, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartEst.
Feb 25, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07413666
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 25, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 25, 2026

Study contacts

ORX489 Centessa Program Lead ORX489 Centessa Program Lead
Contact
ORX489-101study@centessa.com
617-468-5770
Celerion Program Lead CA49982 United States, Nebraska [Recruiting]
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion